• ORR by irRC. • PFS by RECIST Version 1.1 . • PFS by irRC. • OS. • DOR by RECIST Version 1.1 and irRC. • DCR (confirmed CR, PR, or stable disease [SD] lasting for at least 2 months) by RECIST Version 1.1 and irRC . • QoL by PROs. NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 4 Confidential and Proprietary 9 Exploratory Endpoints: • Tumor molecular profiles and correlations with subject outcomes. • Therapy- induced changes in immune responses and correlations with subject outcomes. • Molecular chan ges in ctDNA and ctRNA and correlations with subject outcomes. Phase 2 Primary Endpoint: • ORR by RECIST Version 1.1. Secondary Endpoints: • ORR by irRC. • PFS by RECIST Version 1.1 . • PFS by irRC. • OS. • DOR by RECIST Version 1.1 and irRC. • DCR (confirmed CR, PR, or SD lasting for at least 2 months) by RECIST Version 1.1 and irRC. • QoL by PROs. • Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03. Exploratory Endpoints: • Tumor molecular profiles and correlations with subject outcomes. • Therapy- induced changes in immune responses and correlations with subject outcomes. • Molecular changes in ctDNA and ctRNA and correlations with subject outcomes. In the phase 1b portion of the study, response will be assessed by a local independent radiolog ist; in the phase 2 portion of the study, the primary assessment of response will be based on BICR. A charter for the conduct of BICR will be prepared by the vendor selected to perform the independent review. Enrollment (planned): In the phase 1b portion of the study, 6 to 24 subjects will be enrolled. The initial 3 subjects will be enrolled in a staggered fashion, with a 21- day interval between each subject. In the phase 2 portion of the study, 23 subjects will be enrolled in the first stage of Simon’s tw o-stage optimal design. If the study proceeds to the second stage of Simon’s two -stage optimal design, an additional 32 subjects will be enrolled in the second stage, for a total of 55 subjects in the phase 2 portion of the study. The maximum total enrollm ent for the study is 79 subjects. Eligibility Criteria: Inclusion Criteria: 1. Age ≥ 18 years old.